Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Patent
1995-04-06
1997-10-14
Fitzgerald, David L.
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
536 235, 530351, 424 852, 930141, 435 6951, 435 697, C12N 1524, C07K 1454, A61K 3820
Patent
active
056771495
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to mutants or variants of human interleukin-3 (hIL-3) which contain one or more amino acid substitutions and which may have portions of the native hIL-3 molecule deleted. These hIL-3 single and multiple mutation polypeptides retain one or more activities of native hIL-3 and may also show improved hematopoietic cell-stimulating activity and/or an improved activity profile which may include reduction of undesirable biological activities associated with native hIL-3.
BACKGROUND OF THE INVENTION
Colony stimulating factors (CSFs) which stimulate the differentiation and/or proliferation of bone marrow cells have generated much interest because of their therapeutic potential for restoring depressed levels of hematopoietic stem cell-derived cells. CSFs in both human and murine systems have been identified and distinguished according to their activities. For example, granulocyte-CSF (G-CSF) and macrophage-CSF (M-CSF) stimulate the in vitro formation of neutrophilic granulocyte and macrophage colonies, respectively while GM-CSF and interleukin-3 (IL-3) have broader activities and stimulate the formation of both macrophage, neutrophilic and eosinophilic granulocyte colonies. IL-3 also stimulates the formation of mast, megakaryocyte and pure and mixed erythroid colonies.
Because of its ability to stimulate the proliferation of a number of different cell types and to support the growth and proliferation of progenitor cells, IL-3 has potential for therapeutic use in restoring hematopoietic cells to normal amounts in those cases where the number of cells has been reduced due to diseases or to therapeutic treatments such as radiation and chemotherapy.
Interleukin-3 (IL-3) is a hematopoietic growth factor which has the property of being able to promote the survival, growth and differentiation of hematopoietic cells. Among the biological properties of IL-3 are the ability (a) to support the growth and differentiation of progenitor cells committed to all, or virtually all, blood cell lineages; (b) to interact with early multipotential stem cells; (c) to sustain the growth of pluripotent precursor cells; (d) to stimulate proliferation of chronic myelogenous leukemia (CML) cells; (e) to stimulate proliferation of mast cells, eosinophils and basophils; (f) to stimulate DNA synthesis by human acute myelogenous leukemia (AML) cells; (g) to prime cells for production of leukotrienes and histamines; (h) to induce leukocyte chemotaxis; and (i) to induce cell surface molecules needed for leukocyte adhesion.
Mature human interleukin-3 (hIL-3) consists of 133 amino acids. It has one disulfide bridge and two potential glycosylation sites (Yang, et al., CELL 47:3 (1986)).
Murine IL-3 (mIL-3) was first identified by Ihle, et al., J. IMMUNOL. 126:2184 (1981) as a factor which induced expression of a T cell associated enzyme, 20-hydroxysteroid dehydrogenase. The factor was purified to homogeneity and shown to regulate the growth and differentiation of numerous subclasses of early hematopoietic and lymphoid progenitor cells.
In 1984, cDNA clones coding for murine IL-3 were isolated (Fung, et al., NATURE 307:233 (1984) and Yokota, et al., PROC. NATL. ACAD. SCI. USA81:1070 (1984)). The murine DNA sequence coded for a polypeptide of 166 amino acids including a putative signal peptide.
The gibbon IL-3 sequence was obtained using a gibbon cDNA expression library. The gibbon IL-3 sequence was then used as a probe against a human genomic library to obtain a human IL-3 sequence.
Gibbon and human genomic DNA homologues of the murine IL-3 sequence were disclosed by Yang, et al., CELL 47:3 (1986). The human sequence reported by Yang, et al. included a serine residue at position 8 of the mature protein sequence. Following this finding, others reported isolation of Pro.sup.8 hIL-3 cDNAs having proline at position 8 of the protein sequence. Thus it appears that there may be two allelic forms of hIL-3.
Dorssers, et al., GENE 55:115 (1987), found a clone from a human cDNA library which hybridized with
REFERENCES:
patent: 4877729 (1989-10-01), Clark et al.
patent: 4959455 (1990-09-01), Clark et al.
patent: 5032395 (1991-07-01), Clark et al.
patent: 5166322 (1992-11-01), Shaw et al.
Yang et al, in Cell 47:3 (1986).
Dorsers et al, Gene 55:115 (1987).
Phillips et al, Gene, 84, 501 (1989).
Clark-Lewis et al, Science 231:134 (1986).
Clark-Lewis et al, Proc. Nat. Acad. Sci. USA 85:7897 (1988).
Lokker et al, J. Biol. Chem., 266(16):10624 (1991).
Clark-Lewis et al, Immune Regulation by Characterized Polypeptides, Alan R. Liss, Inc. (1987) pp. 323-334.
Ihle et al, J. Immunol. 126:2184 (1981).
Fung et al, Nature, 307, 233 (1984).
Yokota et al, Proc. Nat. Acad. Sci. USA 81:1070 (1984).
Dorssers et al, J. Biol. Chem 266(31):21310 (1991).
Koshansky et al, J. Clin. Invest, 90:1879 (1992).
Lopez et al, Proc. Natl. Acad. Sci. USA 89:11842-11846 (1992).
Lokker et al, The EMBO Jour. 10:2125-2131 (1991).
Olins, P.O., et al. (1995) J. Biol. Chem. 270:23754-60.
Abrams Mark Allen
Bauer S. Christopher
Braford-Goldberg Sarah Ruth
Caparon Maire Helena
Easton Alan Michael
Bennett Dennis A.
Fitzgerald David L.
G.D. Searle & Co.
LandOfFree
Interleukin-3 (IL-3) mutant polypeptides and their recombinant p does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interleukin-3 (IL-3) mutant polypeptides and their recombinant p, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interleukin-3 (IL-3) mutant polypeptides and their recombinant p will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1554324